Skip Navigation LinksHome > September 2012 - Volume 112 - Issue 9 > Cancer Drug Lenalidomide May Increase Risk of Second Primary...
AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000418924.37977.af
Drug Watch

Cancer Drug Lenalidomide May Increase Risk of Second Primary Malignancies

Aschenbrenner, Diane S. MS, RN

Collapse Box

Abstract

* The label of lenalidomide (Revlimid) now carries a warning that patients taking the drug for multiple myeloma have a heightened risk of new primary cancers.

© 2012 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Article Level Metrics